Psychedelics
Psilocybin Therapy Still Benefits People With Depression One Year After Treatment, Study Finds
Almost all participants reported feeling significantly less depressed when they met up with the researchers a week after treatment, and most continued to report lower depression scores 3 months, 6 months, and 12 months after their psilocybin trip.
The DEA Wants to Add Five More Psychedelics to Schedule I Controlled Substances List
While the DEA says that these drugs all “have a high potential for abuse,” advocates argue that the new rule could lead to more harm than good.
Ketamine Therapy Rapidly Reduces Suicidal Ideation, Study Finds
Patients hospitalized for severe suicidal ideation could benefit from ketamine transfusions, according to new research led by scientists at the University of Montpellier.
Fish on Acid? Microdosing Zebrafish With LSD Shows Its Potential Benefits for Humans
Trevor James Hamilton, an associate professor in neuroscience at MacEwan University, discusses his research into how LSD affects zebrafish – and the implications it could have for mental health treatment.
The Rise of Sponsored Psychedelic Studies Could Bias Research, Warn Psychiatrists
The field of psychedelic drug research is experiencing a renaissance. But this could come at a cost of scientific integrity, argue some researchers.
Antidepressant Psychedelics Could Be Separated From Hallucinations, Suggest Researchers
Researchers have found potentially non-hallucinatory psychedelic compounds by examining crystal structures.
Ketamine and Psilocybin Could Boost the “Integration of New Experiences” By Stimulating Nerves in the Brain
Research from Alex Kwan’s lab has suggested that dendritic plasticity may help support the idea that ketamine and psilocybin can help individuals adopt new perspectives and better process new experiences.
MDMA and Psilocybin Use Linked to Lower Odds of Suicidal Thoughts, Survey Finds
Lifetime use of MDMA is linked to fewer suicidal thoughts, according to the US survey study.
Ketamine Therapy Helps Promote Alcohol Abstinence, Trial Finds
The alcohol-use disorder trial, run by Awakn Life Sciences, has reported its first findings, and it seems like ketamine is a promising treatment.
